Open access
Open access
Powered by Google Translator Translator

Chest Medicine

Opinion: COVID-19 will continue but the end of the pandemic is near.

21 Jan, 2022 | 10:16h | UTC

COVID-19 will continue but the end of the pandemic is near – The Lancet

 

Commentary on Twitter

 


Europe considers new COVID-19 strategy: Accepting the virus.

21 Jan, 2022 | 10:13h | UTC

Europe considers new COVID-19 strategy: Accepting the virus – Associated Press

 


Review: Postdischarge Evaluation for Individuals Hospitalized with COVID-19.

21 Jan, 2022 | 10:08h | UTC

Postdischarge Evaluation for Individuals Hospitalized with COVID-19 – Southern Medical Journal

 


ATS Guideline: Outpatient respiratory management of infants, children, and adolescents with post-prematurity respiratory disease.

21 Jan, 2022 | 09:55h | UTC

Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline – American Journal of Respiratory and Critical Care Medicine

News Release: Outpatient Management of Patients with Post-Prematurity Respiratory Disease: American Thoracic Society Publishes New Clinical Practice Guideline

 


Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

 


A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.

20 Jan, 2022 | 09:30h | UTC

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

 

Commentary on Twitter

 


Milder disease with Omicron: is it the virus or the pre-existing immunity?

20 Jan, 2022 | 09:28h | UTC

Milder disease with Omicron: is it the virus or the pre-existing immunity? – Nature Reviews Immunology

 


How does Omicron spread so fast? A high viral load isn’t the answer – “Data on viral levels point to immune evasion as a cause of the variant’s transmissibility”.

20 Jan, 2022 | 09:27h | UTC

How does Omicron spread so fast? A high viral load isn’t the answer – Nature

 


Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

20 Jan, 2022 | 09:25h | UTC

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Related:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 


Review: Evaluating the patient with a pulmonary nodule.

20 Jan, 2022 | 08:56h | UTC

Evaluating the Patient With a Pulmonary Nodule: A Review – JAMA (free for a limited period)

Author Interview: Evaluation and Management of Patients With Pulmonary Nodules

 


COVID-19 testing infographics.

19 Jan, 2022 | 08:59h | UTC

COVID-19 testing infographics – British Society for Immunology

 

Commentary on Twitter

 


RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.

19 Jan, 2022 | 08:56h | UTC

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA

Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay

 


Fact check: The theory that SARS-CoV-2 is becoming milder.

19 Jan, 2022 | 08:44h | UTC

Fact check: The theory that SARS-CoV-2 is becoming milder – NPR

 


Systematic Review: Intermittent prophylactic antibiotics for bronchiectasis.

19 Jan, 2022 | 08:33h | UTC

Intermittent prophylactic antibiotics for bronchiectasis – Cochrane Library

Summary: Long term antibiotics taken at regular intervals by people with bronchiectasis – Cochrane Library

 


Practical guide to cardiopulmonary exercise testing in adults.

19 Jan, 2022 | 08:26h | UTC

Practical guide to cardiopulmonary exercise testing in adults – Respiratory Research

 


[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

18 Jan, 2022 | 09:59h | UTC

Israel Finds Fourth COVID Booster is Ineffective, While Hospitalised Omicron Patients Fare Much Better Than Delta Patients – Health Policy Watch

See also:

Israeli trial, world’s first, finds 4th dose ‘not good enough’ against Omicron – The Times of Israel

Israel study: 4th vaccine shows limited results with omicron – MedicalXpress

 


COVID-19 updated evidence: a Cochrane round-up.

18 Jan, 2022 | 09:53h | UTC

COVID-19 evidence: a Cochrane round-up – Cochrane Library

 


Study raises doubts about rapid Covid tests’ reliability in early days after infection.

18 Jan, 2022 | 09:51h | UTC

Study raises doubts about rapid Covid tests’ reliability in early days after infection – STAT

Original Article (preprint): Discordant SARS-CoV-2 PCR and Rapid Antigen Test Results When Infectious: A December 2021 Occupational Case Series – medRxiv

 


Time to upgrade from cloth and surgical masks to respirators? Your questions answered.

18 Jan, 2022 | 09:48h | UTC

Time to upgrade from cloth and surgical masks to respirators? Your questions answered – The Conversation

See also: The CDC updated its mask guidelines. What to know about ‘the highest level of protection’ – CNN

Related: CDC urges Americans to wear most-protective mask or respirator that fits well and that they’ll wear consistently.

 


Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

18 Jan, 2022 | 09:41h | UTC

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 – Annals of Internal Medicine

Editorial: The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia – Annals of Internal Medicine

 


ASCO Guideline: Management of stage III non–small-cell lung cancer.

18 Jan, 2022 | 09:12h | UTC

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline – Journal of Clinical Oncology

 


WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

17 Jan, 2022 | 00:48h | UTC

News release: WHO recommends two new drugs to treat COVID-19 – World Health Organization

Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ

Commentaries:

WHO Recommends Two New COVID-19 Treatments – Cost and Availability Likely Barriers – Health Policy Watch

Expert reaction to WHO recommending two drugs, sotrovimab and baricitinib, to treat patients with COVID-19 – Science Media Centre

 

Commentary on Twitter (thread – click for more)

 


Viewpoint: COVID-19 therapeutics for nonhospitalized patients.

17 Jan, 2022 | 00:31h | UTC

COVID-19 Therapeutics for Nonhospitalized Patients – JAMA

Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA

 


New UK Guidance: Self-isolation for those with COVID-19 can end after 5 full days following 2 negative rapid lateral flow tests – “The default self-isolation period continues to be 10 days, and you may only leave self-isolation early if you have taken 2 rapid lateral flow tests and do not have a temperature in line with guidance”.

14 Jan, 2022 | 08:48h | UTC

Self-isolation for those with COVID-19 can end after 5 full days following 2 negative LFD tests – Department of Health and Social Care

 

Commentary on Twitter (thread – click for more)

 


Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

14 Jan, 2022 | 08:37h | UTC

Fluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario

Related:

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.